Target intelligence / Profile preview

C-terminal-binding protein 1 (CtBP1)

Target
CtBP1
Molecular classification
Transcription factor (transcriptional corepressor), Enzyme (dehydrogenase activity), Other (membrane trafficking protein)
01

Overview

C-terminal-binding protein 1 (CtBP1) is an evolutionarily conserved transcriptional corepressor and metabolic sensor encoded by the CTBP1 gene. CtBP1 is recruited to gene promoters by sequence-specific transcription factors and mediates transcriptional repression by interacting with chromatin-modifying complexes, including histone deacetylases and polycomb group proteins[1][2][5]. Its corepressor function is regulated by its binding to NADH, enabling CtBP1 to sense cellular metabolic states and coordinate gene expression with energy status[1][7]. CtBP1 plays critical roles in development, cell differentiation, cell proliferation, regulation of mitochondrial function, and membrane trafficking (particularly as BARS)[1][2][5][7]. Overexpression or hyperactivity of CtBP1 is associated with cancer, as it represses tumor suppressor genes, promotes epithelial-mesenchymal transition, and enhances tumor cell migration and metastasis[3][4]. Several preclinical small molecule inhibitors have been developed targeting CtBP1, notably in cancer research[3]. Loss of function mutations are linked to developmental disorders, while broad inhibition poses significant safety challenges due to its central regulatory roles.

Other names
CtBP1CTBPBARSbrefeldin A-ribosylated substrateHADDTSC-terminal binding protein 1
02

Mechanism of action

Inhibition of transcriptional corepressor function (restores tumor suppressor expression, blocks oncogenic repression). Inhibition of dehydrogenase enzymatic activity.

03

Biological functions

Transcriptional repression (corepressor activity)Epigenetic regulation (via chromatin modification)Cell differentiationCell proliferationRegulation of epithelial-mesenchymal transitionMetabolic sensing (senses NADH/NAD+ ratio)Maintenance of mitochondrial activityMembrane trafficking and fission
04

Disease associations

Cancer (oncogene activity, tumor suppressor repression)Developmental disorders (e.g., hypotonia, ataxia, developmental delay, tooth enamel defect syndrome)Wolf-Hirschhorn syndromeOther developmental abnormalities
05

Safety considerations

Ubiquitous expression and essential developmental roles may lead to toxicity if systemically inhibitedDisruption may affect fundamental gene regulation and cell survival
06

Interacting drugs

Small molecule inhibitors in preclinical development (no approved drugs as of 2024) [3]
07

Biomarkers

CtBP1 expression (potential biomarker for cancer progression and therapy response) [3]

Beyond the preview

Go deeper on C-terminal-binding protein 1 (CtBP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-terminal-binding protein 1 (CtBP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call